[Malignant hyperthermia].
D000293:Adolescent; D000328:Adult; D000368:Aged; D000777:Anesthetics / Q000009:adverse effects / Q000494:pharmacology; D001706:Biopsy; D002648:Child; D002675:Child, Preschool; D002800:Cholinesterase Inhibitors / Q000009:adverse effects / Q000494:pharmacology; D002802:Cholinesterases / Q000172:deficiency / Q000235:genetics; D003620:Dantrolene / Q000627:therapeutic use; D003937:Diagnosis, Differential; D005260:Female; D005334:Fever / Q000139:chemically induced / Q000175:diagnosis; D006801:Humans; D006980:Hyperthyroidism / Q000175:diagnosis; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008305:Malignant Hyperthermia / Q000175:diagnosis / Q000209:etiology / Q000235:genetics / Q000503:physiopathology / Q000628:therapy; D008875:Middle Aged; D009119:Muscle Contraction / Q000187:drug effects; D009132:Muscles / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D009467:Neuromuscular Depolarizing Agents / Q000009:adverse effects / Q000494:pharmacology; D010013:Osteogenesis Imperfecta / Q000175:diagnosis; D011229:Preanesthetic Medication
D000777:Anesthetics; D002800:Cholinesterase Inhibitors; D009467:Neuromuscular Depolarizing Agents; D002802:Cholinesterases; D003620:Dantrolene
Hipertermia maligna.